InfoRMS

Key	Summary	Description	Resolution	Resolution Description
PS-210	DiagnosticReport.Status Not Fixed in CA Core, Fixed =Final in PS-CA	Summary: DiagnosticReport.Status Not Fixed in CA Core, Fixed =Final in PS-CA Existing Wording: Proposed Wording: Comment: DiagnosticReport.Status Not Fixed in CA Core, Fixed =Final in PS-CA IPS CI build changed to not fixed; previously fixed = "final"; PS-CA should change back to not fixed. Submitted by: Kenn Sinn Infoway	Persuasive	Agreed, the fixed constraint will be removed
PS-199	Suggest to remove	Summary: Suggest to remove Existing Wording: Comments See additionalBinding extension. IPS-UV no longer flags this as a Must Support element. It is not currently flagged as Must Support in PS-CA, as stakeholders have indicated the element may not be supported by the majority of systems today. Systems that do support the element are encouraged to include it in generated Patient Summary documents, and support it when received. Proposed Wording: Comments See additionalBinding extension. Comment: Suggest to remove Submitted by: Linda Parisien Canada Health Infoway	Persuasive	This is the comment for route - remove the two indicated paragraphs: IPS-UV no longer flags this as a Must Support element. It is not currently flagged as Must Support in PS-CA, as stakeholders have indicated the element may not be supported by the majority of systems today. Systems that do support the element are encouraged to include it in generated Patient Summary documents, and support it when received.
PS-196	Changed for the current valueset definition	Summary: Changed for the current valueset definition Existing Wording: Binding The site at which the vaccine was administered. Proposed Wording: Binding The anatomical site where the immunizing agent was administered. CodesForImmunizationSiteOfAdministration (example)ImmunizationAdministeredAnatomicalSiteCode Comment: Changed for the current valueset definition Submitted by: Myriam Talantikit Canada Health Infoway	Persuasive	Agreed. Update definition
PS-195	Not relevant anymore, suggest to remove	Summary: Not relevant anymore, suggest to remove Existing Wording: Comments The development of a FHIR ValueSet & Terminology Gateway subset for this element is underway. Given that the migration of terminology from the CVC to NVC is underway, and that this element is no longer MS in PS-CA or IPS, the profiling on this binding has been temporarily removed and will be reapplied in future updates once there is an established subset to point to. Proposed Wording: delete Comment: Not relevant anymore, suggest to remove Submitted by: Myriam Talantikit Canada Health Infoway	Persuasive	Agreed, the text will be removed
PS-192	Add valueset current definition	Summary: Add valueset current definition Existing Wording: PassiveHistoricalImmunizingAgentCode (preferred) Equivalently recommended for use when conveying when passive immunization products are used. Proposed Wording: PassiveHistoricalImmunizingAgentCode (preferred) This refset is intended to capture the immunization history and includes concepts represented by a generic description for a passive immunizing agent that was previously administered to the client Comment: Add valueset current definition and remove the old paragraph Submitted by: Myriam Talantikit Canada Health Infoway	Persuasive	Agreed, text description will be updated as proposed PassiveHistoricalImmunizingAgentCode (preferred) _This refset is intended to capture the immunization history and includes concepts represented by a generic description for a passive immunizing agent that was previously administered to the client_
PS-191	Add valueset current definition	Summary: Add valueset current definition Existing Wording: PassiveAdministeredImmunizingAgentCode (preferred) Equivalently recommended for use when conveying when passive immunization products are used. Proposed Wording: PassiveAdministeredImmunizingAgentCode (preferred) This refset is intended to capture the product administered at the point of immunization and includes the passive immunizing agent tradenames that are currently licensed for use in Canada, those obtained through special access programs for use in Canada, and those that were never licensed in Canada. Comment: Add valueset current definition and remove the old paragraph Submitted by: Myriam Talantikit Canada Health Infoway	Persuasive	Agreed, text description will be updated as proposed PassiveAdministeredImmunizingAgentCode (preferred) _This refset is intended to capture the product administered at the point of immunization and includes the passive immunizing agent tradenames that are currently licensed for use in Canada, those obtained through special access programs for use in Canada, and those that were never licensed in Canada._
PS-190	Add valueset current definition	Summary: Add valueset current definition Existing Wording: VaccineHistoricalNameCode (preferred) Equivalently recommended for use when conveying vaccine generic names for scenarios when brand names…. Proposed Wording: VaccineHistoricalNameCode (preferred) This refset is intended to capture the immunization history and includes concepts represented by a generic description for a vaccine that was previously administered to the client Comment: Add valueset current definition and remove the old paragraph Submitted by: Myriam Talantikit Canada Health Infoway	Persuasive	Agreed, text description will be updated as proposed VaccineHistoricalNameCode (preferred) _This refset is intended to capture the immunization history and includes concepts represented by a generic description for a vaccine that was previously administered to the client_
PS-189	Suggest removing these additional bindings as mentioned below	Summary: Suggest removing these additional bindings as mentioned below Existing Wording: Comments See additionalBinding extension. Future releases of PS-CA may require use of coded entries. In this release, however, implementations that support codings are encouraged to send the codings for codeable concepts if they are available. Consistent with FHIR best practice, receivers should not produce failures or rejections if codings are received. Vendors should expect that some jurisdictions may further constrain support of this element within the context of their own jurisdictional content. IPS-UV Note: Several kinds of vaccine product coding could be provided. The IPS assumes that either the type of the vaccine for particular disease or diseases (e.g. MMR vaccine) against which the patient has been immunized is provided; or the known absent/unknown. Other coded information can be provided as well as: 1. The IDMP Pharmaceutical Product Identifier (PhPID), Level 1, [Substance(s)]. Example: Amoxicillin and Clavulanate Potassium; or any other equivalent coded concept. 2. The IDMP Pharmaceutical Product Identifier (PhPID), Level 2 [Substance(s) + Strength + reference strength]. Example: Amoxicillin 875 mg and Clavulanate Potassium 125 mg; or any other equivalent coded concept. 3. The IDMP Pharmaceutical Product Identifier (PhPID), Level 3 [Substance(s) + administrable dose form]. Example: Amoxicillin and Clavulanate Potassium, Oral Tablet; or any other equivalent coded concept. 4. The IDMP Pharmaceutical Product Identifier (PhPID), Level 4 [Substance(s) + strength + reference strength + administrable dose form]. Example: Amoxicillin 875 mg and clavulanate potassium 125 mg, oral tablet; or any other equivalent coded concept. 5. The IDMP Medicinal Product Identifier (MPID) or any equivalent Medicinal Product Identifier. IDMP MPID uniquely identifies a Medicinal Product, reflecting (but not replacing) any other authorization numbers allocated by a regulator. MPID implies one (set of) PhPID. The MPID shall use a common segment pattern related to a Medicinal Product, which, when each segment is valued shall define a specific MPID concept. 6. The IDMP Packaged Medicinal Product Identifier (PCID) or any equivalent Packaged Medicinal Product Identifier. Uniquely identifies a Medicinal Product based on its packaging. This implies one MPID can be associated with more than one PCID, if the same Medicinal Product has more than one type of package. 7. Any other kind of code that that identifies, classifies or clusters the administered product (e.g. the medicinal product or the product class). The value sets used for the PhPID, MPID and PCID identifiers are provisional and include only few equivalent concepts used for exemplification purposes, they will be updated with real IDMP identifiers when they will become available. Proposed Wording: delete Comment: Suggest removing these additional bindings as mentioned below Submitted by: Myriam Talantikit Canada Health Infoway	Not Persuasive	The set of bindings should remain. The removal of the IDMP text is covered by ticket PS-152
PS-188	Suggest to remove this text as in CA we are not using the IPS-UV vaccine concepts, because that would be a partial set of codes. No Canadian Trade names or Brand names would be available from that set of codes	Summary: Suggest to remove this text as in CA we are not using the IPS-UV vaccine concepts, because that would be a partial set of codes. No Canadian Trade names or Brand names would be available from that set of codes Existing Wording: IPS-UV Note: Several kinds of vaccine product coding could be provided. The IPS assumes that either the type of the vaccine for particular disease or diseases (e.g. MMR vaccine) against which the patient has been immunised is provided; or the known absent/unknown code. Other coded information can be provided as well as: the Pharmaceutical and medicinal product identifiers, when available, or equivalent coded concepts; the WHO ATC codes; or any other kind of code that that identifies, classifies or cluster the administered product. Proposed Wording: delete Comment: Suggest to remove this text as in CA we are not using the IPS-UV vaccine concepts, because that would be a partial set of codes. No Canadian Trade names or Brand names would be available from that set of codes. I would add here the note on the 4 Infoway valuesets that should be used in CA: Note: VaccineHistoricalNameCode, PassiveAdministeredImmunizingAgentCode, and PassiveHistoricalImmunizingAgentCode equivalently preferred to the primary binding as they convey codes that are intended to be utilized in different contexts (e.g., passive agents) Submitted by: Linda Parisien Canada Health Infoway	Not Persuasive with Modification	Keep the IPS text and add: _The IPS-UV vaccine concepts are not used in Canadian implementations as they do not include Canadian trade or brand names. Implementers should use the following pan-Canadian value sets, depending on context: "VaccineHistoricalNameCode", "PassiveAdministeredImmunizingAgentCode", and "PassiveHistoricalImmunizingAgentCode", which are equivalently preferred alongside the primary binding._
PS-186	Infoway valuesets for different scope for Route of administration.	Summary: Infoway valuesets for different scope for Route of administration. Existing Wording: EDQM route of administration MedicineRouteOfAdministrationUvIps, HL7 v3 route of administration v3.RouteOfAdministration Proposed Wording: delete Comment: Infoway has developed multiple valuesets for different scope for Route of administration. The only binding should be the preferred one above. EDQM is not in use in Canada per say, SNOMED CT CA is aligned with EDQM. Submitted by: Linda Parisien Canada Health Infoway	Not Persuasive with Modification	Keep the additional bindings, but add a note: " While this additional binding is not primarily used in the Canadian healthcare context, it is retained to support potential use of PS-CA internationally and IPS within Canada. Implementers should be aware that this binding may not comprehensively represent all Canadian route of administration codes"
PS-185	Suggestion to delete all this paragraph as it is not relevant anymore	Summary: Suggestion to delete all this paragraph as it is not relevant anymore Existing Wording: The development of a FHIR ValueSet & Terminology Gateway subset for this element is underway. Given that the migration of terminology from the CVC to NVC is underway, and that this element is no longer MS in PS-CA or IPS, the profiling on this binding has been temporarily removed and will be re-applied in future updates once there is an established subset to point to. Proposed Wording: delete Comment: Suggestion to delete all this paragraph as it is not relevant anymore Submitted by: Myriam Talantikit Canada Health Infoway	Persuasive	Agreed, the identified text will be removed from the site element.
PS-184	Addition: current existing valueset for anatomical site codes	Summary: Addition: current existing valueset for anatomical site codes Existing Wording: Proposed Wording: Added preferred binding of ImmunizationAdministrationAnatomicalSiteCode Comment: Addition: current existing valueset for anatomical site codes Submitted by: Myriam Talantikit Canada Health Infoway	Persuasive with Modification	Add ImmunizationAdministrationAnatomicalSiteCode as preferred binding
PS-183	In Canada, we have developed vaccine concepts that would not be available from any of the IPS Vaccine Code, not the WHO ATC	Summary: In Canada, we have developed vaccine concepts that would not be available from any of the IPS Vaccine Code, not the WHO ATC Existing Wording: IPS Vaccine Code VaccinesUvIps - WHO ATC WhoAtcUvIps Proposed Wording: delete Comment: In Canada, we have developed vaccine concepts that would not be available from any of the IPS Vaccine Code, not the WHO ATC. Providing these bindings, means that only partial information on vaccine could be captured.If we decide to still keep these above bindings in the PS-CA, a Note to that effect should be provided. Submitted by: Linda Parisien Canada Health Infoway	Not Persuasive with Modification	Keep the bindings and add a note highlighting that the WHO ATC WhoAtcUvIps does not provide coverage for all vaccines used in Canada.
PS-152	There’s significant text around the use of IDMP levels, which aren’t used in Canada.	Summary: There’s significant text around the use of IDMP levels, which aren’t used in Canada. Existing Wording: Proposed Wording: Comment: There’s significant text around the use of IDMP levels, which aren’t used in Canada. SNOMED is currently mapping to IDMP as well. Suggest all the content around IDMP be removed if it is not applicable, as it may confuse or overwhelm readers/implementers. They were included in PS-CA because the IPS mentions them all (https://build.fhir.org/ig/HL7/fhir-ips/StructureDefinition-Immunization-uv-ips-definitions.html#key_Immunization.vaccineCode) – but IPS has no included any bindings to them to date. Submitted by: Linda Parisien Myriam Talantikit Infoway	Persuasive	Remove the IPS UV note text in its entirety

DiagnosticReport.Status Not Fixed in CA Core, Fixed =Final in PS-CA

Summary: DiagnosticReport.Status Not Fixed in CA Core, Fixed =Final in PS-CA
Existing Wording:
Proposed Wording:
Comment: DiagnosticReport.Status Not Fixed in CA Core, Fixed =Final in PS-CA
IPS CI build changed to not fixed; previously fixed = "final"; PS-CA should change back to not fixed.
Submitted by: Kenn Sinn
Infoway

Persuasive

Agreed, the fixed constraint will be removed

PS-199

Suggest to remove

Summary: Suggest to remove
Existing Wording: Comments
See additionalBinding extension.
IPS-UV no longer flags this as a Must Support element. It is not currently flagged as Must Support in PS-CA, as stakeholders have indicated the element may not be supported by the majority of systems today.
Systems that do support the element are encouraged to include it in generated Patient Summary documents, and support it when received.
Proposed Wording: Comments
See additionalBinding extension.
Comment: Suggest to remove
Submitted by: Linda Parisien
Canada Health Infoway

Persuasive

This is the comment for route - remove the two indicated paragraphs:

IPS-UV no longer flags this as a Must Support element. It is not currently flagged as Must Support in PS-CA, as stakeholders have indicated the element may not be supported by the majority of systems today.

Systems that do support the element are encouraged to include it in generated Patient Summary documents, and support it when received.

PS-196

Changed for the current valueset definition

Summary: Changed for the current valueset definition
Existing Wording: Binding
The site at which the vaccine was administered.
Proposed Wording: Binding
The anatomical site where the immunizing agent was administered.
CodesForImmunizationSiteOfAdministration (example)ImmunizationAdministeredAnatomicalSiteCode
Comment: Changed for the current valueset definition
Submitted by: Myriam Talantikit
Canada Health Infoway

Persuasive

Agreed. Update definition

PS-195

Not relevant anymore, suggest to remove

Summary: Not relevant anymore, suggest to remove
Existing Wording: Comments
The development of a FHIR ValueSet & Terminology Gateway subset for this element is underway. Given that the migration of terminology from the CVC to NVC is underway, and that this element is no longer MS in PS-CA or IPS, the profiling on this binding has been temporarily removed and will be reapplied in future updates once there is an established subset to point to.
Proposed Wording: delete
Comment: Not relevant anymore, suggest to remove
Submitted by: Myriam Talantikit
Canada Health Infoway

Persuasive

Agreed, the text will be removed

PS-192

Add valueset current definition

Summary: Add valueset current definition
Existing Wording: PassiveHistoricalImmunizingAgentCode (preferred)
Equivalently recommended for use when conveying when passive immunization products are used.
Proposed Wording: PassiveHistoricalImmunizingAgentCode (preferred)
This refset is intended to capture the immunization history and includes concepts represented by a generic description for a passive immunizing agent that was previously administered to the client
Comment: Add valueset current definition and remove the old paragraph
Submitted by: Myriam Talantikit
Canada Health Infoway

Persuasive

Agreed, text description will be updated as proposed

PassiveHistoricalImmunizingAgentCode (preferred)
_This refset is intended to capture the immunization history and includes concepts represented by a generic description for a passive immunizing agent that was previously administered to the client_

PS-191

Add valueset current definition

Summary: Add valueset current definition
Existing Wording: PassiveAdministeredImmunizingAgentCode (preferred)
Equivalently recommended for use when conveying when passive immunization products are used.
Proposed Wording: PassiveAdministeredImmunizingAgentCode (preferred)
This refset is intended to capture the product administered at the point of immunization and includes the passive immunizing agent tradenames that are currently licensed for use in Canada, those obtained through special access programs for use in Canada, and those that were never licensed in Canada.
Comment: Add valueset current definition and remove the old paragraph
Submitted by: Myriam Talantikit
Canada Health Infoway

Persuasive

Agreed, text description will be updated as proposed

PassiveAdministeredImmunizingAgentCode (preferred)
_This refset is intended to capture the product administered at the point of immunization and includes the passive immunizing agent tradenames that are currently licensed for use in Canada, those obtained through special access programs for use in Canada, and those that were never licensed in Canada._

PS-190

Add valueset current definition

Summary: Add valueset current definition
Existing Wording: VaccineHistoricalNameCode (preferred)
Equivalently recommended for use when conveying vaccine generic names for scenarios when brand names….
Proposed Wording: VaccineHistoricalNameCode (preferred)
This refset is intended to capture the immunization history and includes concepts represented by a generic description for a vaccine that was previously administered to the client
Comment: Add valueset current definition and remove the old paragraph
Submitted by: Myriam Talantikit
Canada Health Infoway

Persuasive

Agreed, text description will be updated as proposed

VaccineHistoricalNameCode (preferred)
_This refset is intended to capture the immunization history and includes concepts represented by a generic description for a vaccine that was previously administered to the client_

PS-189

Suggest removing these additional bindings as mentioned below

Summary: Suggest removing these additional bindings as mentioned below
Existing Wording: Comments
See additionalBinding extension.
Future releases of PS-CA may require use of coded entries. In this release, however, implementations that support codings are encouraged to send the codings for codeable concepts if they are available. Consistent with FHIR best practice, receivers should not produce failures or rejections if codings are received. Vendors should expect that some jurisdictions may further constrain support of this element within the context of their own jurisdictional content.
IPS-UV Note: Several kinds of vaccine product coding could be provided.
The IPS assumes that either the type of the vaccine for particular disease or diseases (e.g. MMR vaccine) against which the patient has been immunized is provided; or the known absent/unknown.
Other coded information can be provided as well as:
1. The IDMP Pharmaceutical Product Identifier (PhPID), Level 1, [Substance(s)]. Example: Amoxicillin and Clavulanate Potassium; or any other equivalent coded concept.
2. The IDMP Pharmaceutical Product Identifier (PhPID), Level 2 [Substance(s) + Strength + reference strength]. Example: Amoxicillin 875 mg and Clavulanate Potassium 125 mg; or any other equivalent coded concept.
3. The IDMP Pharmaceutical Product Identifier (PhPID), Level 3 [Substance(s) + administrable dose form]. Example: Amoxicillin and Clavulanate Potassium, Oral Tablet; or any other equivalent coded concept.
4. The IDMP Pharmaceutical Product Identifier (PhPID), Level 4 [Substance(s) + strength + reference strength + administrable dose form]. Example: Amoxicillin 875 mg and clavulanate potassium 125 mg, oral tablet; or any other equivalent coded concept.
5. The IDMP Medicinal Product Identifier (MPID) or any equivalent Medicinal Product Identifier. IDMP MPID uniquely identifies a Medicinal Product, reflecting (but not replacing) any other authorization numbers allocated by a regulator. MPID implies one (set of) PhPID. The MPID shall use a common segment pattern related to a Medicinal Product, which, when each segment is valued shall define a specific MPID concept.
6. The IDMP Packaged Medicinal Product Identifier (PCID) or any equivalent Packaged Medicinal Product Identifier. Uniquely identifies a Medicinal Product based on its packaging. This implies one MPID can be associated with more than one PCID, if the same Medicinal Product has more than one type of package.
7. Any other kind of code that that identifies, classifies or clusters the administered product (e.g. the medicinal product or the product class).
The value sets used for the PhPID, MPID and PCID identifiers are provisional and include only few equivalent concepts used for exemplification purposes, they will be updated with real IDMP identifiers when they will become available.
Proposed Wording: delete
Comment: Suggest removing these additional bindings as mentioned below
Submitted by: Myriam Talantikit
Canada Health Infoway

Not Persuasive

The set of bindings should remain. The removal of the IDMP text is covered by ticket PS-152

PS-188

Suggest to remove this text as in CA we are not using the IPS-UV vaccine concepts, because that would be a partial set of codes. No Canadian Trade names or Brand names would be available from that set of codes

Summary: Suggest to remove this text as in CA we are not using the IPS-UV vaccine concepts, because that would be a partial set of codes. No Canadian Trade names or Brand names would be available from that set of codes
Existing Wording: IPS-UV Note: Several kinds of vaccine product coding could be provided. The IPS assumes that either the type of the vaccine for particular disease or diseases (e.g. MMR vaccine) against which the patient has been immunised is provided; or the known absent/unknown code. Other coded information can be provided as well as: the Pharmaceutical and medicinal product identifiers, when available, or equivalent coded concepts; the WHO ATC codes; or any other kind of code that that identifies, classifies or cluster the administered product.
Proposed Wording: delete
Comment: Suggest to remove this text as in CA we are not using the IPS-UV vaccine concepts, because that would be a partial set of codes. No Canadian Trade names or Brand names would be available from that set of codes.

I would add here the note on the 4 Infoway valuesets that should be used in CA: Note: VaccineHistoricalNameCode, PassiveAdministeredImmunizingAgentCode, and PassiveHistoricalImmunizingAgentCode equivalently preferred to the primary binding as they convey codes that are intended to be utilized in different contexts (e.g., passive agents)
Submitted by: Linda Parisien
Canada Health Infoway

Not Persuasive with Modification

Keep the IPS text and add:

_The IPS-UV vaccine concepts are not used in Canadian implementations as they do not include Canadian trade or brand names. Implementers should use the following pan-Canadian value sets, depending on context: "VaccineHistoricalNameCode", "PassiveAdministeredImmunizingAgentCode", and "PassiveHistoricalImmunizingAgentCode", which are equivalently preferred alongside the primary binding._

PS-186

Infoway valuesets for different scope for Route of administration.

Summary: Infoway valuesets for different scope for Route of administration.
Existing Wording: EDQM route of administration MedicineRouteOfAdministrationUvIps,
HL7 v3 route of administration v3.RouteOfAdministration
Proposed Wording: delete
Comment: Infoway has developed multiple valuesets for different scope for Route of administration. The only binding should be the preferred one above.

EDQM is not in use in Canada per say, SNOMED CT CA is aligned with EDQM.
Submitted by: Linda Parisien
Canada Health Infoway

Not Persuasive with Modification

Keep the additional bindings, but add a note:

" While this additional binding is not primarily used in the Canadian healthcare context, it is retained to support potential use of PS-CA internationally and IPS within Canada. Implementers should be aware that this binding may not comprehensively represent all Canadian route of administration codes"

PS-185

Suggestion to delete all this paragraph as it is not relevant anymore

Summary: Suggestion to delete all this paragraph as it is not relevant anymore
Existing Wording: The development of a FHIR ValueSet & Terminology Gateway subset for this element is underway. Given that the migration of terminology from the CVC to NVC is underway, and that this element is no longer MS in PS-CA or IPS, the profiling on this binding has been temporarily removed and will be re-applied in future updates once there is an established subset to point to.
Proposed Wording: delete
Comment: Suggestion to delete all this paragraph as it is not relevant anymore
Submitted by: Myriam Talantikit
Canada Health Infoway

Persuasive

Agreed, the identified text will be removed from the site element.

PS-184

Addition: current existing valueset for anatomical site codes

Summary: Addition: current existing valueset for anatomical site codes
Existing Wording:
Proposed Wording: Added preferred binding of ImmunizationAdministrationAnatomicalSiteCode
Comment: Addition: current existing valueset for anatomical site codes
Submitted by: Myriam Talantikit
Canada Health Infoway

Persuasive with Modification

Add ImmunizationAdministrationAnatomicalSiteCode as preferred binding

PS-183

In Canada, we have developed vaccine concepts that would not be available from any of the IPS Vaccine Code, not the WHO ATC

Summary: In Canada, we have developed vaccine concepts that would not be available from any of the IPS Vaccine Code, not the WHO ATC
Existing Wording: IPS Vaccine Code VaccinesUvIps
- WHO ATC WhoAtcUvIps
Proposed Wording: delete
Comment: In Canada, we have developed vaccine concepts that would not be available from any of the IPS Vaccine Code, not the WHO ATC.
Providing these bindings, means that only partial information on vaccine could be captured.If we decide to still keep these above bindings in the PS-CA, a Note to that effect should be provided.
Submitted by: Linda Parisien
Canada Health Infoway

Not Persuasive with Modification

Keep the bindings and add a note highlighting that the WHO ATC WhoAtcUvIps does not provide coverage for all vaccines used in Canada.

PS-152

There’s significant text around the use of IDMP levels, which aren’t used in Canada.

Summary: There’s significant text around the use of IDMP levels, which aren’t used in Canada.
Existing Wording:
Proposed Wording:
Comment: There’s significant text around the use of IDMP levels, which aren’t used in Canada. SNOMED is currently mapping to IDMP as well. Suggest all the content around IDMP be removed if it is not applicable, as it may confuse or overwhelm readers/implementers. They were included in PS-CA because the IPS mentions them all (https://build.fhir.org/ig/HL7/fhir-ips/StructureDefinition-Immunization-uv-ips-definitions.html#key_Immunization.vaccineCode) – but IPS has no included any bindings to them to date.
Submitted by: Linda Parisien
Myriam Talantikit
Infoway

Persuasive

Remove the IPS UV note text in its entirety


InfoRMS
Displaying 14 issues at 16/Jul/25 11:22 AM.